Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Pasireotide (as pamoate) (Signifor®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue. |
|||
|
|||
Medicine details |
|||
| Medicine name | pasireotide (Signifor®) | ||
| Formulation | 20 mg, 40 mg, 60 mg powder and solvent for suspension for injection | ||
| Reference number | 643 | ||
| Indication | Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1316 | ||
| NMG meeting date | 20/01/2016 | ||
| AWMSG meeting date | 18/05/2016 | ||
| Ratification by Welsh Government | 10/06/2016 | ||
| Date of issue | 15/06/2016 | ||
| Date of last review | 21/06/2019 | ||